Novel Mechanisms of Nuclear Phosphoinositide Signaling in Regulation of the YAP/TAZ Pathway in Triple-negative Breast Cancer
核磷酸肌醇信号传导调节三阴性乳腺癌 YAP/TAZ 通路的新机制
基本信息
- 批准号:10579376
- 负责人:
- 金额:$ 36.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-01 至 2023-07-19
- 项目状态:已结题
- 来源:
- 关键词:1-Phosphatidylinositol 3-Kinase1-Phosphatidylinositol 4-KinaseAmino AcidsApoptosisBindingBiochemicalBiologicalBiological AssayBiological ProcessBreast Cancer CellBreast Cancer TreatmentCRISPR/Cas technologyCell DeathCell NucleusCell ProliferationCell modelCellsDevelopmentDrug TargetingEnzymesGene ExpressionGenesHumanInositol PhosphatesInvestigationKnock-outKnowledgeLipidsMediatingMolecularMolecular TargetMusMutagenesisNatureNebraskaNuclearPI3 genePathogenesisPathway interactionsPatientsPharmacologyPhosphatidylinositolsPhosphoinositide PathwayPhosphotransferasesPhysiologyProteinsRegulationSignal TransductionSiteTherapeuticXenograft procedurebasebreast cancer progressioncancer cellcell motilitychemotherapydruggable targetfunctional outcomesmalignant breast neoplasmmethod developmentmouse modelmutantnew therapeutic targetnovelphosphatidylinositol phosphate 4-kinasetargeted cancer therapytargeted treatmenttherapeutic developmenttranscriptome sequencingtriple-negative invasive breast carcinomatumorigenesis
项目摘要
Phosphoinositides (PIs) are lipid messengers that control many aspects of human physiology. A significant
fraction of PIs (>40% of total PIs) is found in the nucleus, however the nature and functions of the nuclear
PIs are largely unknown. We discovered that phosphatidylinositol 4,5-bisphosphate (PI4,5P2) is an
abundant PI species in the nucleus and the PI4,5P2-generating kinase phosphatidylinositol-4-phosphate-5-
kinase type 1 alpha (PIPKI) is a major enzyme modulating nuclear PI4,5P2 signaling. Nuclear PI4,5P2 can
be further phosphorylated by a nuclear-localizing PI3-kinase (PI3K) inositol phosphate multikinase (IPMK)
to produce a PI species, PI3,4,5P3, that has been implicated in oncogenesis. This suggests that PIPKI
and IPMK are potential targets for cancer therapy. Consistently, we showed that depletion or
pharmacological inhibition of PIPKI and IPMK leads to cancer cell death by apoptosis in triple negative
breast cancer (TNBC) cells. Moreover, in TNBC cells, we discovered that depletion of PIPKI and IPMK
significantly reduces the expression of YAP/TAZ target genes that have established contributions to
oncogenesis. TNBC is the most aggressive subtype of breast cancer and associated with poor patient
survival due to lack of alternatives to current chemotherapies. As a result, there is an urgent need for
discovering novel targeted therapeutics in TNBC. The YAP/TAZ-PI kinases (PIPKI and IPMK) pathways
are attractive drug targets because aberrant activation of YAP/TAZ is frequently found in breast cancer
particularly in TNBC, PIPKI gene is commonly amplified in TNBC, and the nuclear PI3,4,5P3 pathway is
frequently deregulated in TNBC. Precise understanding of nuclear PIs-mediated YAP/TAZ pathway will
provide knowledge which can be utilized for developing targeted therapeutics against TNBC. In this
proposal, we will 1) elucidate molecular mechanisms by which the YAP/TAZ pathway is controlled by
PIPIK and IPMK via extensive biochemical and cell biological approaches and 2) investigate contributions
of PIPIK and IPMK in TNBC pathogenesis in cultured TNBC cells and mouse models.
磷酸肌醇 (PI) 是控制人体生理机能许多方面的脂质信使。一个重要的
部分 PI(> 总 PI 的 40%)存在于细胞核中,但是细胞核的性质和功能
PI 在很大程度上是未知的。我们发现磷脂酰肌醇 4,5-二磷酸 (PI4,5P2) 是一种
细胞核中丰富的 PI 种类和 PI4,5P2 生成激酶 磷脂酰肌醇-4-磷酸-5-
1 型 α 激酶 (PIPKI) 是调节核 PI4,5P2 信号传导的主要酶。核PI4、5P2可以
被核定位 PI3 激酶 (PI3K) 磷酸肌醇多激酶 (IPMK) 进一步磷酸化
产生与肿瘤发生有关的 PI 物种 PI3,4,5P3。这表明 PIPKI �
和IPMK是癌症治疗的潜在靶点。一致地,我们表明耗尽或
PIPKI 和 IPMK 的药理抑制可导致三阴性细胞凋亡导致癌细胞死亡
乳腺癌(TNBC)细胞。此外,在 TNBC 细胞中,我们发现 PIPKI 和 IPMK 的耗尽
显着降低 YAP/TAZ 靶基因的表达,这些基因已确定对
肿瘤发生。 TNBC 是乳腺癌中最具侵袭性的亚型,与贫困患者相关
由于缺乏当前化疗的替代方案而导致生存。因此,迫切需要
发现 TNBC 的新型靶向疗法。 YAP/TAZ-PI 激酶(PIPKI 和 IPMK)途径
是有吸引力的药物靶点,因为 YAP/TAZ 的异常激活经常在乳腺癌中发现
特别是在 TNBC 中,PIPKI 基因在 TNBC 中普遍扩增,核 PI3,4,5P3 通路为
TNBC 经常放松管制。准确理解核 PI 介导的 YAP/TAZ 通路将有助于
提供可用于开发针对 TNBC 的靶向疗法的知识。在这个
建议,我们将1)阐明YAP/TAZ途径受控的分子机制
PIPIK™ 和 IPMK 通过广泛的生化和细胞生物学方法进行研究,2) 研究贡献
在培养的 TNBC 细胞和小鼠模型中,PIPIK 和 IPMK 在 TNBC 发病机制中的作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Suyong Choi其他文献
Suyong Choi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Suyong Choi', 18)}}的其他基金
Unexpected roles of phosphoinositides in the nucleus
磷酸肌醇在细胞核中的意外作用
- 批准号:
10711033 - 财政年份:2023
- 资助金额:
$ 36.88万 - 项目类别:
PIP5K1A is a novel mutant KRAS effector and essential for pancreatic cancer cell survival
PIP5K1A 是一种新型突变型 KRAS 效应子,对于胰腺癌细胞的生存至关重要
- 批准号:
10666257 - 财政年份:2023
- 资助金额:
$ 36.88万 - 项目类别:
Novel Mechanisms of Nuclear Phosphoinositide Signaling in the Regulation of the YAP/TAZ Pathway in Triple-Negative Breast Cancer
核磷酸肌醇信号传导调节三阴性乳腺癌 YAP/TAZ 通路的新机制
- 批准号:
10714241 - 财政年份:2018
- 资助金额:
$ 36.88万 - 项目类别:














{{item.name}}会员




